Experiments and synthesis of bone-targeting epirubicin with the water-soluble macromolecular drug delivery systems of oxidized-dextran

References

• Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol 2010;8:705–18
   PubMedGoogle Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in highgrade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002;20:776–90
   PubMed Web of Science ®Google Scholar
• Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 2008;134:281–97
   PubMed Web of Science ®Google Scholar
• Basaran M, Bavbek ES, Saglam S, et al. A phase II study of cisplatin, ifosfamide and epirubicin combination chemotherapy in adults with nonmetastaticand extremity osteosarcomas. Oncology 2007;72:255–60
   PubMed Web of Science ®Google Scholar
• Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs 2007;18:737–44
   PubMed Web of Science ®Google Scholar
• Wang D, Miller SC, Kopecková P, Kopecek J. Bone-targeting macromolecular therapeutics. Adv Drug Deliv Rev 2005;57:1049–76
   PubMed Web of Science ®Google Scholar
• Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347–60
   PubMed Web of Science ®Google Scholar
• Low SA, Kopeček J. Targeting polymer therapeutics to bone. Adv Drug Deliv Rev 2012;64:1189–204
   PubMed Web of Science ®Google Scholar
• Wu H, Zhang Z, Wu D, et al. Preparation and drug release characteristics of Pingyangmycin-loaded dextran cross-linked gelatin microspheres for embolization therapy. J Biomed Mater Res B Appl Biomater 2006;78:56–62
   PubMedGoogle Scholar
• Varshosaz J. Dextran conjugates in drug delivery. Expert Opin Drug Deliv 2012;9:509–23
   PubMed Web of Science ®Google Scholar
• Uludag H. Bisphosphonates as a foundation of drug delivery to bone. Curr Pharm Des 2002;8:1929–44
   PubMed Web of Science ®Google Scholar
• Hengst V, Oussoren C, Kissel T, Storm G.Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 2007;331:224–7
   Google Scholar
• Miller K, Erez R, Segal E, et al. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate-taxane conjugate. Angew Chem Int Ed Engl 2009;48:2949–54
   PubMed Web of Science ®Google Scholar
• Heymann D, Ory B, Gouin F, et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med 2004;10:337–43
   PubMed Web of Science ®Google Scholar
• Clézardin P, Ebetino FH, Fournier PG. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005;65:4971–4
   PubMed Web of Science ®Google Scholar
• Zhao H, Heindel ND. Determination of degree of substitution of formyl groups in polyaldehyde dextran by the hydmxylamine hydroehloride method. Pharma Res 1991;8:400–2
   Google Scholar
• Shinoda H, Adamek G, Felix R, et al. Structure activity relationships of various bisphosphonates. Calcif Tissue Int 1983;35:87–99
   PubMed Web of Science ®Google Scholar
• Fujisawa R, Wada Y, Nodasaka Y, Kuboki Y. Acidic amino acid-rich sequences as binding sites of osteonectin to hydroxyapatite crystals. Biochim Biophys Acta 1996;1292:53–60
   PubMed Web of Science ®Google Scholar
• Yuan XB, Li H, Zhu XX, Woo HG. Self-aggregated nanoparticles composed of periodate-oxidized dextran and cholic acid: preparation, stabilization and in-vitro drug release. J Chem Technol Biotechnol 2006;81:746–54
   Web of Science ®Google Scholar
• Chen FZ, Cai L, Sun JH, Zhang KY. Investigation on the preparation and properties of adriamycin-dextran-tetracycline conjugate. J Math Med 2006;19:294–6
   Google Scholar
• Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 2011;49:34–41
   PubMed Web of Science ®Google Scholar
• Nakajima H, Magae J, Tsuruga M, et al. Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett 2007;253:89–96
   PubMed Web of Science ®Google Scholar
• Cheng YY, Huang L, Lee KM, et al. Bisphosphonates induce apoptosis of stromal tumor cells in giant cell tumor of bone. Calcif Tissue Int 2004;75:71–7
   PubMed Web of Science ®Google Scholar
• Edwin MP, William LD, James G. The emerging role of bisphosphonates in prostate cancer. Am J Ther 2004;11:60–73
   PubMedGoogle Scholar
• Tenta R, Sourla A, Lembessis P, et al. Bone microenviroment-related growth factors, zoledronic acid and dexamethasone differentially modulate PTHrP expression in PC-3 prostate cancer cells. Horm Metab Res 2005;37:593–601
   PubMed Web of Science ®Google Scholar
• Sanders JM, Subhash G, Julian MWC, et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem 2004;47:375–84
   PubMed Web of Science ®Google Scholar
• Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006;27:92–103
   PubMed Web of Science ®Google Scholar
• Segal E, Pan H, Benayoun L, et al. Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances. Biomaterials 2011;32:4450–63
   PubMed Web of Science ®Google Scholar
• Segal E, Pan H, Ofek P, et al. Targeting angiogenesis-dependent calcified neoplasms using combined polymer therapeutics. PLoS One 2009;4:e5233
   PubMed Web of Science ®Google Scholar
• Lown JW. Anthracycline and anthraquinone anticancer agents: current status and recent developments. Pharmacol Ther 1993;60:185–214
   PubMed Web of Science ®Google Scholar
• Nielsen D, Maare C, Skovsgaard T. Cellular resistance to anthracyclines. Gen Pharmacol 1996;27:251–5
   PubMedGoogle Scholar
• Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727–41
   PubMed Web of Science ®Google Scholar
• Rivera E. Implications of anthracycline-resistant and taxane-resistant metastatic breast cancer and new therapeutic options. Breast J 2010;16:252–63
   PubMed Web of Science ®Google Scholar
• Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24:5664–71
   PubMed Web of Science ®Google Scholar
• Cersosimo RJ, Hong WK. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of anadriamycin analogue. J Clin Oncol 1986;4:425–39
   PubMed Web of Science ®Google Scholar
• Kremer LC, van Dalen EC, Offringa M, et al. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19:191–6
   PubMed Web of Science ®Google Scholar
• Vert M. Polyvalent polymeric drug carriers. Crit Rev Ther Drug Carrier Syst 1986;2:291–327
   PubMedGoogle Scholar
• Mehvar R. Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives. Curr Pharm Biotechnol 2003;4:283–302
   PubMedGoogle Scholar
• Lam W, Leung CH, Chan HL, Fong WF. Toxicity and DNA binding of dextran-doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran size. Anticancer Drugs 2000;11:377–84
   PubMed Web of Science ®Google Scholar
• Bisht S, Maitra A. Dextran-doxorubicin/chitosan nanoparticles for solid tumor therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:415–25
   PubMed Web of Science ®Google Scholar
• Ueda Y, Munechika K, Kikukawa A, et al. Comparison of efficacy, toxicity and pharmacokinetics of free adriamycin and adriamycin linked to oxidized dextran in rats. Chem Pharm Bull (Tokyo) 1989;37:1639–41
   PubMed Web of Science ®Google Scholar
• Danhauser-Riedl S, Hausmann E, Schick HD, et al. Phase I clinical and pharmacokinetic trial of dextran conjugated doxorubicin (AD-70, DOX-OXD). Invest New Drugs 1993;11:187–95
   PubMed Web of Science ®Google Scholar
• Wang D, Miller S, Sima M, et al. Synthesis and evaluation of water-soluble polymeric bone-targeted drug delivery systems. Bioconjug Chem 2003;14:853–9
   PubMed Web of Science ®Google Scholar
• Perrin RA. Binding of tetracycline to bone. Nature 1965;208:787–8
   PubMed Web of Science ®Google Scholar